Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

Shares of Amgen Inc. AMGN rallied 1.03% to $280.35 Wednesday, on what proved to be an all-around mixed trading session for ...

AI partners Microsoft and OpenAI’s cooling relationship cools further with Amgen’s switch from Copilot to ChatGPT.

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Shares of Amgen (AMGN) fell on Monday after announcing that its weight-loss drug will move into a phase 3 trial, with ...